Ipilimumab for the treatment of advanced melanoma in six kidney transplant patients
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Ipilimumab for the treatment of advanced melanoma in six kidney transplant patients
Authors
Keywords
-
Journal
AMERICAN JOURNAL OF TRANSPLANTATION
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2018-08-15
DOI
10.1111/ajt.15071
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immune checkpoint inhibitor therapy in a liver transplant recipient with a rare subtype of melanoma
- (2018) James C. Kuo et al. MELANOMA RESEARCH
- Preserved Renal-Allograft Function and the PD-1 Pathway Inhibitor Nivolumab
- (2017) Richard Barnett et al. NEW ENGLAND JOURNAL OF MEDICINE
- Use of the PD-1 Pathway Inhibitor Nivolumab in a Renal Transplant Patient With Malignancy
- (2016) C. L. Boils et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Checkpoint Inhibitors in Kidney Transplant Recipients and the Potential Risk of Rejection
- (2016) T. Alhamad et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma
- (2016) L. Spain et al. ANNALS OF ONCOLOGY
- Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report
- (2016) Taofeek K. Owonikoko et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Tumor Regression and Allograft Rejection after Administration of Anti–PD-1
- (2016) Evan J. Lipson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Renal Allograft Failure After Ipilimumab Therapy for Metastatic Melanoma: A Case Report and Review of the Literature
- (2016) A. Jose et al. TRANSPLANTATION PROCEEDINGS
- Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
- (2016) Lucie Heinzerling et al. Journal for ImmunoTherapy of Cancer
- Antitumor activity of nivolumab on hemodialysis after renal allograft rejection
- (2016) Michael Ong et al. Journal for ImmunoTherapy of Cancer
- Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
- (2015) Troy Z. Horvat et al. JOURNAL OF CLINICAL ONCOLOGY
- Administration of Ipilimumab to a Liver Transplant Recipient With Unresectable Metastatic Melanoma
- (2015) Harsha A. Ranganath et al. JOURNAL OF IMMUNOTHERAPY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation
- (2015) Rita E Morales et al. Journal for ImmunoTherapy of Cancer
- Successful Administration of Ipilimumab to Two Kidney Transplantation Patients With Metastatic Melanoma
- (2014) Evan J. Lipson et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Melanoma in Organ Transplant Recipients: Clinicopathological Features and Outcome in 100 Cases
- (2008) R. N. Matin et al. AMERICAN JOURNAL OF TRANSPLANTATION
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started